![]() |
|
|
EM Hoenicke, SA Vanecek and JH Woods
Department of Pharmacology, University of Michigan Medical School, Ann Arbor.
Pigeons were trained to discriminate i.m. injections of the atypical antipsychotic clozapine (1.0 mg/kg) from saline in a two-key operant procedure. In substitution tests, compounds that shared antagonistic action at 5-hydroxytryptamine (5-HT)1C and 5-HT2 receptors produced discriminative stimulus effects similar to clozapine: cyproheptadine, metergoline, mianserin, pizotifen and fluperlapine. 5-HT antagonists selective for 5-HT2 vs. 5-HT1C receptors (e.g., ketanserin, pirenperone, risperidone and methiothepin) failed to produce substantial clozapine-appropriate responding. Other serotonergic compounds failed to produce substantial clozapine-appropriate responding: the 5-HT3 antagonist, ondansetron; the 5-HT1A agonists, (+- )-8-hydroxy-2-(di-n-propylamino)tetralin and BMY 14802; the 5-HT1A/1B agonist, RU24969; the 5-HT1A partial agonist, NAN190; the 5-HT1C/2 antagonist, mesulergine; the 5-HT1 agonist, I-5-hydroxytryptophane; and the 5-HT1C/2 agonist, quipazine. Other reference compounds such as the typical antipsychotics, chlorpromazine and thioridazine; the selective dopamine D-2 antagonists, droperidol and sulpiride; the dopamine D-1 antagonist, SCH 23390; the antimuscarinics, atropine and scopolamine; the antihistamines, pyrilamine and diphenhydramine; the alpha-1 antagonist, prazosin; and the antidepressants, imipramine and chloromipramine also failed to produce clozapine-appropriate responding. Promethazine, cinanserin and amitriptyline produced only partial generalization to the clozapine cue. The results suggest that blockade of both 5-HT2 and/or 5-HT1C receptors is important in the pharmacological mediation of the discriminative stimulus effects of clozapine. Blockade of 5-HT2 receptors appears not to be sufficient to produce clozapine-like discriminative stimulus effects. The precise role of 5-HT1C receptors in the clozapine discriminative stimulus is unclear due to the lack of compounds selective for this receptor.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
![]() |
M. J. Millan, R. Schreiber, S. Monneyron, B. Denorme, C. Melon, S. Queriaux, and A. Dekeyne S-16924, a Novel, Potential Antipsychotic with Marked Serotonin1A Agonist Properties. IV. A Drug Discrimination Comparison with Clozapine J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 427 - 436. [Abstract] [Full Text] |
||||
![]() |
M. J. Millan, R. Schreiber, A. Dekeyne, J.-M. Rivet, K. Bervoets, M. Mavridis, C. Sebban, S. Maurel-Remy, A. Newman-Tancredi, M. Spedding, et al. S 16924 ((R)-2-{1-[2-(2,3-Dihydro-Benzo[1,4] Dioxin-5-Yloxy)-Ethyl]-Pyrrolidin-3yl}-1-(4-Fluoro-Phenyl)-Ethanone), a Novel, Potential Antipsychotic with Marked Serotonin (5-HT)1A Agonist Properties: II. Functional Profile in Comparison to Clozapine and Haloperidol J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1356 - 1373. [Abstract] [Full Text] |
||||
![]() |
S. A. Vanecek, W. D. Essman, D. P. Taylor, and J. H. Woods Discriminative Stimulus Characteristics of BMY 14802 in the Pigeon J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 1 - 9. [Abstract] [Full Text] |
||||
![]() |
C. Cohen, D. J. Sanger, and G. Perrault Characterization of the Discriminative Stimulus Produced by the Dopamine Antagonist Tiapride J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 566 - 573. [Abstract] [Full Text] |
||||
![]() |
A. H. Tang, S. R. Franklin, C. S. Himes, M. W. Smith, and R. E. Tenbrink PNU-96415E, a Potential Antipsychotic Agent with Clozapine-Like Pharmacological Properties J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 440 - 447. [Abstract] [Full Text] |
||||